{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T13:14:53Z","timestamp":1789391693304,"version":"build-2803163510"},"reference-count":59,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>JAK inhibitors have emerged as a promising new therapy for inflammatory skin disease, including in pediatric populations. However, due to their boxed warnings and lack of long-term safety and efficacy data, their specific role in the treatment ladder for various conditions remains to be determined.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>JAK inhibitors are currently approved for pediatric atopic dermatitis and alopecia areata with evidence of both efficacy and safety. They are currently being investigated for use in children with vitiligo, psoriasis, juvenile dermatomyositis, and hidradenitis suppurativa. So far, no significant safety concerns, especially regarding the FDA-mandated black box warnings, have been observed in pediatric patients being treated for inflammatory skin disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>JAK inhibitors provide clinicians and patients with another tool to consider when faced with challenging inflammatory skin diseases. Place in therapy amid the current armamentarium of available treatments for select skin conditions is evolving, as efficacy and safety data accumulates in trials and clinicians develop more real-world experience. As of now, use of JAK inhibitors should be considered on a case-by-case basis after a comprehensive assessment of the benefits and potential risks.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mop.0000000000001474","type":"journal-article","created":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T08:00:10Z","timestamp":1750060810000},"page":"373-379","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Oral JAK inhibitors for pediatric inflammatory skin disease"],"prefix":"10.1097","volume":"37","author":[{"given":"Erica B.","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly M.","family":"Cordoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,6,9]]},"reference":[{"key":"R1-20250819","doi-asserted-by":"crossref","first-page":"8555","DOI":"10.1073\/pnas.87.21.8555","article-title":"ISGF3, the transcriptional activator induced by interferon alpha, consists of multiple interacting polypeptide chains","volume":"87","author":"Fu","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R2-20250819","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"R3-20250819","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.3389\/fimmu.2019.02847","article-title":"Emerging topical and systemic JAK inhibitors in dermatology","volume":"10","author":"Solimani","year":"2019","journal-title":"Front Immunol"},{"key":"R4-20250819","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/gb-2004-5-12-253","article-title":"The Janus kinases (Jaks)","volume":"5","author":"Yamaoka","year":"2004","journal-title":"Genome Biol [Internet]"},{"key":"R5-20250819","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.3390\/jcm10194307","article-title":"Role of Janus kinase inhibitors in therapy of psoriasis","volume":"10","author":"S\u0142uczanowska-G\u0142abowska","year":"2021","journal-title":"J Clin Med"},{"key":"R6-20250819","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1080\/17512433.2023.2193682","article-title":"JAK inhibitors in dermatology: the road travelled and path ahead, a narrative review","volume":"16","author":"Muddebihal","year":"2023","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R9-20250819","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1001\/jamadermatol.2023.0391","article-title":"Efficacy and safety of upadacitinib treatment in adolescents with moderate-to-severe atopic dermatitis: analysis of the measure up 1, measure up 2, and AD up randomized clinical trials","volume":"159","author":"Paller","year":"2023","journal-title":"JAMA Dermatol"},{"key":"R10-20250819","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1001\/jamadermatol.2024.3696","article-title":"Upadacitinib in adolescents with moderate to severe atopic dermatitis: analysis of 3 phase 3 randomized clinical trials through 76 weeks","volume":"160","author":"Paller","year":"2024","journal-title":"JAMA Dermatol"},{"key":"R11-20250819","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1007\/s12325-023-02490-5","article-title":"Real-life effectiveness and tolerance of upadacitinib for severe atopic dermatitis in adolescents and adults","volume":"40","author":"De Greef","year":"2023","journal-title":"Adv Ther"},{"key":"R12-20250819","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s40261-024-01382-y","article-title":"Effectiveness and safety of upadacitinib for adolescents with atopic dermatitis in a real-world setting","volume":"44","author":"Patruno","year":"2024","journal-title":"Clin Drug Investig"},{"key":"R13-20250819","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.clinthera.2024.07.003","article-title":"Pharmacokinetics, safety, tolerability, and exploratory efficacy of upadacitinib in children with severe atopic dermatitis","volume":"46","author":"Qian","year":"2024","journal-title":"Clin Ther"},{"key":"R14-20250819","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.3390\/jcm12031175","article-title":"Efficacy and treatment satisfaction of different systemic therapies in children and adolescents with moderate-to-severe atopic dermatitis: a real-world study","volume":"12","author":"Kiefer","year":"2023","journal-title":"J Clin Med"},{"key":"R15-20250819","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/cea.14518","article-title":"Upadacitinib for refractory paediatric atopic dermatitis: a real-world study on effectiveness and safety in dupilumab nonresponders","volume":"54","author":"Zhao","year":"2024","journal-title":"Clin Exp Allergy"},{"key":"R18-20250819","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1001\/jamadermatol.2021.2830","article-title":"Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: the JADE TEEN Randomized Clinical Trial","volume":"157","author":"Eichenfield","year":"2021","journal-title":"JAMA Dermatol [Internet]"},{"key":"R19-20250819","doi-asserted-by":"crossref","first-page":"2200866","DOI":"10.1080\/09546634.2023.2200866","article-title":"Efficacy and safety of abrocitinib monotherapy in adolescents and adults: a post hoc analysis of the phase 3 JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN clinical trial","volume":"34","author":"Flohr","year":"2023","journal-title":"J Dermatol Treat"},{"key":"R20-20250819","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/pde.15761","article-title":"A case series of refractory pediatric atopic dermatitis effectively treated with dupilumab in combination with abrocitinib","volume":"42","author":"Fong","year":"2024","journal-title":"Pediatr Dermatol"},{"key":"R21-20250819","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/bjd\/ljad096","article-title":"Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS)","volume":"189","author":"Torrelo","year":"2023","journal-title":"Br J Dermatol"},{"key":"R22-20250819","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/pde.15386","article-title":"Use of tofacitinib in baricitinib-refractory atopic dermatitis: an example of JAK inhibitor switching","volume":"41","author":"Dhir","year":"2024","journal-title":"Pediatr Dermatol"},{"key":"R25-20250819","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/pde.15378","article-title":"Efficacy and safety of ritlecitinib in adolescents with alopecia areata: results from the ALLEGRO phase 2b\/3 randomized, double-blind, placebo-controlled trial","volume":"40","author":"Hordinsky","year":"2023","journal-title":"Pediatr Dermatol"},{"key":"R27-20250819","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.jaad.2022.12.033","article-title":"Treatment of moderate-to-severe alopecia areata in adolescents with baricitinib: a retrospective review of 29 patients","volume":"88","author":"Moussa","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"R28-20250819","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/bjd\/ljad118","article-title":"Treatment of moderate-to-severe alopecia areata in preadolescent children with baricitinib","volume":"189","author":"Asfour","year":"2023","journal-title":"Br J Dermatol"},{"key":"R29-20250819","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/jdv.20108","article-title":"Baricitinib therapy for paediatric patients with severe alopecia areata","volume":"39","author":"Zhao","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R30-20250819","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ebiom.2015.02.015","article-title":"Reversal of alopecia areata following treatment with the JAK1\/2 inhibitor baricitinib","volume":"2","author":"Jabbari","year":"2015","journal-title":"EBioMedicine [Internet]"},{"key":"R31-20250819","doi-asserted-by":"crossref","first-page":"1516039","DOI":"10.3389\/fped.2024.1516039","article-title":"Baricitinib in pediatric chronic immune thrombocytopenia and associated autoimmune conditions: a case report","volume":"12","author":"L\u00f3pez de Hontanar Torres","year":"2024","journal-title":"Front Pediatr"},{"key":"R32-20250819","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10875-024-01852-0","article-title":"Baricitinib-induced remission of alopecia universalis in a child with NFKB2-associated immune dysregulation","volume":"45","author":"Blokhuis","year":"2025","journal-title":"J Clin Immunol"},{"key":"R33-20250819","doi-asserted-by":"crossref","first-page":"6644","DOI":"10.1111\/jocd.15425","article-title":"Efficacy and safety of tofacitinib for treatment of alopecia areata in children: a systematic review and meta-analysis","volume":"21","author":"Behrangi","year":"2022","journal-title":"J Cosmet Dermatol"},{"key":"R34-20250819","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1177\/1203475418760512","article-title":"A case report highlighting the effective treatment of alopecia universalis with tofacitinib in an adolescent and adult patient","volume":"22","author":"Patel","year":"2018","journal-title":"J Cutan Med Surg"},{"key":"R35-20250819","first-page":"914","article-title":"An excellent response to tofacitinib in a pediatric alopecia patient: a case report and review -","volume":"17","author":"Liza","year":"2018","journal-title":"J Drugs Dermatol"},{"key":"R36-20250819","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1002\/ccr3.2484","article-title":"An excellent response to tofacitinib in a Brazilian adolescent patient with alopecia areata: a case report and a review of the literature","volume":"7","author":"Berbert Ferreira","year":"2019","journal-title":"Clin Case Rep"},{"key":"R37-20250819","doi-asserted-by":"crossref","first-page":"e13118","DOI":"10.1111\/dth.13118","article-title":"Experience with oral tofacitinib in two adolescents and seven adults with alopecia areata","volume":"32","author":"Akdogan","year":"2019","journal-title":"Dermatol Ther"},{"key":"R38-20250819","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/pde.14855","article-title":"Oral tofacitinib for the treatment of alopecia areata in pediatric patients","volume":"39","author":"Kibbie","year":"2022","journal-title":"Pediatr Dermatol"},{"key":"R39-20250819","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jaad.2021.02.071","article-title":"Alopecia areata flare patterns in children and young adults while on systemic tofacitinib","volume":"86","author":"McKenzie","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"R40-20250819","doi-asserted-by":"crossref","first-page":"135","DOI":"10.4103\/ijt.ijt_15_22","article-title":"Recovery of resistant alopecia areata treated with tofacitinib: an 8-year-old child's case report","volume":"14","author":"Bhokare","year":"2022","journal-title":"Int J Trichol"},{"key":"R41-20250819","doi-asserted-by":"crossref","first-page":"113","DOI":"10.4103\/ijt.ijt_90_23","article-title":"Tofacitinib: a promising treatment for adolescent alopecia areata","volume":"15","author":"Wagh","year":"2023","journal-title":"Int J Trichol"},{"key":"R42-20250819","doi-asserted-by":"crossref","first-page":"e13553","DOI":"10.1111\/srt.13553","article-title":"Tofacitinib treatment in a severe pediatric alopecia areata: A case report and a literature review","volume":"30","author":"Ma","year":"2024","journal-title":"Skin Res Technol"},{"key":"R44-20250819","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/jocd.15896","article-title":"Effective treatment of refractory alopecia areata in pediatric patients with oral abrocitinib","volume":"23","author":"Huang","year":"2024","journal-title":"J Cosmet Dermatol"},{"key":"R45-20250819","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jdcr.2022.02.027","article-title":"A case of atopic dermatitis with alopecia universalis in a patient treated with abrocitinib","volume":"22","author":"Zhao","year":"2022","journal-title":"JAAD Case Rep"},{"key":"R46-20250819","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2147\/JAA.S458684","article-title":"Abrocitinib improved dupilumab-resistant severe atopic dermatitis with comorbid mild alopecia areata in a 12-year-old boy: a case report with 1-year follow-up","volume":"17","author":"Liu","year":"2024","journal-title":"J Asthma Allergy"},{"key":"R47-20250819","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.jaad.2018.08.040","article-title":"Ruxolitinib for the treatment of severe alopecia areata","volume":"80","author":"Liu","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"R48-20250819","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jdcr.2020.02.007","article-title":"Successful treatment of alopecia totalis with ruxolitinib in a preadolescent patient","volume":"6","author":"Peterson","year":"2020","journal-title":"JAAD Case Rep"},{"key":"R49-20250819","doi-asserted-by":"crossref","first-page":"5578","DOI":"10.2340\/actadv.v103.5578","article-title":"Upadacitinib for successful treatment of alopecia universalis in a child: a case report and literature review","volume":"103","author":"Yu","year":"2023","journal-title":"Acta Derm Venereol"},{"key":"R50-20250819","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s13555-023-00889-0","article-title":"Alopecia universalis in an adolescent successfully treated with upadacitinib\u2014a case report and review of the literature on the use of JAK inhibitors in pediatric alopecia areata","volume":"13","author":"Ko\u0142cz Magdalena","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"R51-20250819","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/pde.15504","article-title":"Improvement of severe alopecia areata in an adolescent patient on upadacitinib","volume":"41","author":"Ha","year":"2024","journal-title":"Pediatr Dermatol"},{"key":"R52-20250819","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/ced\/llae309","article-title":"Upadacitinib for the management of severe alopecia areata in adolescent patients: a single-centre retrospective study","volume":"50","author":"Picone","year":"2024","journal-title":"Clin Exp Dermatol"},{"key":"R53-20250819","article-title":"Upadacitinib for the treatment of alopecia areata and severe atopic dermatitis in a paediatric patient: a case report","volume":"10","author":"Bourkas","year":"2022","journal-title":"SAGE Open Med Case Rep"},{"key":"R54-20250819","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.2147\/CCID.S467026","article-title":"Treatment of refractory segmental vitiligo and alopecia areata in a child with upadacitinib and NB-UVB: a case report","volume":"17","author":"Mu","year":"2024","journal-title":"Clin Cosmet Invest Dermatol"},{"key":"R55-20250819","first-page":"1","article-title":"The successful use of upadacitinib as monotherapy for hidradenitis suppurativa and ulcerative colitis in the setting of refractory disease","volume":"0","author":"Ok","year":"2024","journal-title":"Pediatr Dermatol"},{"key":"R56-20250819","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2147\/CCID.S446369","article-title":"Abrocitinib as a novel treatment for multiple skin disorders: 3 case reports and a scoping review","volume":"17","author":"Chen","year":"2024","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"R57-20250819","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1136\/annrheumdis-2020-218690","article-title":"Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis","volume":"80","author":"Kim","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R58-20250819","doi-asserted-by":"crossref","first-page":"962585","DOI":"10.3389\/fped.2022.962585","article-title":"Short-term effectiveness of baricitinib in children with refractory and\/or severe juvenile dermatomyositis","volume":"10","author":"Wang","year":"2022","journal-title":"Front Pediatr"},{"key":"R59-20250819","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1093\/brain\/awz293","article-title":"Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib","volume":"142","author":"Sabbagh","year":"2019","journal-title":"Brain"},{"key":"R60-20250819","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/pde.15469","article-title":"Cutaneous ulceration in juvenile dermatomyositis with antimelanoma differentiation-associated gene 5","volume":"41","author":"Huang","year":"2024","journal-title":"Pediatr Dermatol"},{"key":"R61-20250819","doi-asserted-by":"crossref","first-page":"e140","DOI":"10.1093\/rheumatology\/keaa360","article-title":"A striking treatment option for recalcitrant calcinosis in juvenile dermatomyositis: tofacitinib citrate","volume":"59","author":"S\u00f6zeri","year":"2020","journal-title":"Rheumatology"},{"key":"R62-20250819","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12969-023-00894-9","article-title":"Rapid and sustained response to JAK inhibition in a child with severe MDA5 + juvenile dermatomyositis","volume":"21","author":"Strauss","year":"2023","journal-title":"Pediatr Rheumatol Online J"},{"key":"R64-20250819","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1159\/000503062","article-title":"Tofacitinib in pediatric psoriasis: an open-label trial to study its safety and efficacy in children","volume":"236","author":"Almutairi","year":"2020","journal-title":"Dermatology"},{"key":"R65-20250819","doi-asserted-by":"crossref","first-page":"366","DOI":"10.4103\/ijd.ijd_515_23","article-title":"Use of oral tofacitinib in the treatment of pediatric vitiligo: a case series","volume":"69","author":"Biswal","year":"2024","journal-title":"Indian J Dermatol"},{"key":"R66-20250819","doi-asserted-by":"crossref","first-page":"2200873","DOI":"10.1080\/09546634.2023.2200873","article-title":"Concurrent vitiligo and atopic dermatitis successfully treated with upadacitinib: a case report","volume":"34","author":"Pan","year":"2023","journal-title":"J Dermatol Treat"},{"key":"R69-20250819","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.jaad.2022.06.012","article-title":"Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: a post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials","volume":"87","author":"Mendes-Bastos","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"R70-20250819","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/pde.15721","article-title":"Analysis of publicly available adverse events reported for pediatric patients treated with Janus kinase inhibitors","volume":"41","author":"Talasila","year":"2024","journal-title":"Pediatr Dermatol"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001474","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T18:00:25Z","timestamp":1755626425000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,9]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0000000000001474","relation":{},"ISSN":["1531-698X"],"issn-type":[{"value":"1531-698X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,9]]}}}